pf-06801591,sasanlimab
pfizer
['sasanlimab', 'nmibc', 'mibc', 'crest']
a p3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as a single agent for patients with bcg, unresponsive high-risk, #nmibc: #crest study cohort b. presented by neal shore . #asco22 coverage &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology